This site is intended for healthcare professionals

account_circleSign in
Go to /sign-in page

You can view 5 more pages before signing in

Apixaban for the prevention of venous thromboembolism after total hip or knee replacement

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • apixaban is an anticoagulant that affects the blood coagulation cascade by directly inhibiting activated factor X (factor Xa), so inhibiting thrombin formation and the development of thrombi

  • apixaban has a marketing authorisation for the 'prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery'

  • according to the summary of product characteristics, 11% of patients treated with apixaban 2.5 mg twice daily in clinical trials experienced adverse reactions. As with other anticoagulants, bleeding may occur during apixaban therapy in patients with risk factors such as lesions liable to bleed. Common adverse reactions are anaemia, haemorrhage, contusion and nausea. For full details of side effects and contraindications, see the summary of product characteristics

NICE have stated that "..Apixaban is recommended as an option for the prevention of venous thromboembolism in adults after elective hip or knee replacement surgery.."

Reference:

Related pages

Create an account to add page annotations

Create a free account

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page